Savara Inc. (NASDAQ:SVRA) Given Consensus Rating of "Moderate Buy" by Analysts

Shares of Savara Inc. (NASDAQ:SVRA - Get Free Report) have been given a consensus rating of "Moderate Buy" by the five research firms that are covering the firm, Marketbeat Ratings reports. Two investment analysts have rated the stock with a hold recommendation and three have assigned a buy recommendation to the company. The average 1 year target price among brokers that have updated their coverage on the stock in the last year is $5.60.

Several research analysts have recently commented on the company. HC Wainwright downgraded Savara from a "buy" rating to a "neutral" rating and decreased their price objective for the stock from $6.00 to $2.00 in a report on Thursday, May 29th. Guggenheim reiterated a "buy" rating and issued a $8.00 price objective (down previously from $9.00) on shares of Savara in a research report on Wednesday, May 28th. Evercore ISI lowered their price objective on Savara from $3.00 to $2.00 and set an "in-line" rating for the company in a research report on Wednesday, May 28th. Finally, Wells Fargo & Company lowered their price objective on Savara from $8.00 to $7.00 and set an "overweight" rating for the company in a research report on Wednesday, May 28th.

Insiders Place Their Bets

In other news, Director Richard J. Hawkins bought 48,225 shares of the stock in a transaction on Friday, June 20th. The shares were bought at an average price of $2.04 per share, with a total value of $98,379.00. Following the completion of the acquisition, the director owned 115,466 shares in the company, valued at $235,550.64. The trade was a 71.72% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Corporate insiders own 5.33% of the company's stock.

Institutional Trading of Savara

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Cibc World Markets Corp purchased a new stake in shares of Savara during the fourth quarter worth about $33,000. XTX Topco Ltd purchased a new stake in Savara during the 4th quarter valued at approximately $34,000. Ameriprise Financial Inc. purchased a new stake in Savara during the 4th quarter valued at approximately $37,000. KLP Kapitalforvaltning AS purchased a new stake in Savara during the 4th quarter valued at approximately $41,000. Finally, Hsbc Holdings PLC purchased a new stake in Savara during the 4th quarter valued at approximately $48,000. 87.93% of the stock is owned by hedge funds and other institutional investors.

Savara Price Performance

SVRA stock traded up $0.08 during mid-day trading on Friday, reaching $2.49. 602,340 shares of the company traded hands, compared to its average volume of 1,259,745. The company has a debt-to-equity ratio of 0.20, a current ratio of 14.91 and a quick ratio of 14.91. The company has a market capitalization of $430.37 million, a P/E ratio of -5.19 and a beta of 0.31. Savara has a 52-week low of $1.89 and a 52-week high of $4.74. The company has a fifty day moving average price of $2.38 and a 200-day moving average price of $2.68.

Savara (NASDAQ:SVRA - Get Free Report) last posted its quarterly earnings data on Tuesday, May 13th. The company reported ($0.12) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.12). As a group, analysts anticipate that Savara will post -0.45 earnings per share for the current year.

Savara Company Profile

Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.